IL160363A0 - Expandable gastric retention device - Google Patents

Expandable gastric retention device

Info

Publication number
IL160363A0
IL160363A0 IL16036301A IL16036301A IL160363A0 IL 160363 A0 IL160363 A0 IL 160363A0 IL 16036301 A IL16036301 A IL 16036301A IL 16036301 A IL16036301 A IL 16036301A IL 160363 A0 IL160363 A0 IL 160363A0
Authority
IL
Israel
Prior art keywords
retention device
gastric retention
expandable gastric
expandable
retention
Prior art date
Application number
IL16036301A
Original Assignee
Oregon State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State filed Critical Oregon State
Publication of IL160363A0 publication Critical patent/IL160363A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0419—Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL16036301A 2001-08-16 2001-10-22 Expandable gastric retention device IL160363A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31307801P 2001-08-16 2001-08-16
PCT/US2001/046146 WO2003015745A1 (en) 2001-08-16 2001-10-22 Expandable gastric retention device

Publications (1)

Publication Number Publication Date
IL160363A0 true IL160363A0 (en) 2004-07-25

Family

ID=23214285

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16036301A IL160363A0 (en) 2001-08-16 2001-10-22 Expandable gastric retention device

Country Status (14)

Country Link
EP (1) EP1416914A1 (en)
JP (1) JP2005501097A (en)
KR (1) KR20040032918A (en)
CN (1) CN1543337A (en)
BR (1) BR0117123A (en)
CA (1) CA2456976A1 (en)
CO (1) CO5670360A2 (en)
IL (1) IL160363A0 (en)
MX (1) MXPA04001388A (en)
NO (1) NO20040611L (en)
NZ (1) NZ531461A (en)
PL (1) PL368327A1 (en)
WO (1) WO2003015745A1 (en)
ZA (1) ZA200402066B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466808C (en) 2001-11-21 2009-01-27 E-Z-Em, Inc. Formulations for use in medical or diagnostic procedures
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
US7785291B2 (en) 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US7699863B2 (en) 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
KR20090053783A (en) * 2006-07-19 2009-05-27 스미스클라인 비참 코포레이션 Method for radiolabeling formulations for gamma scintigraphy assesment
CN102552103B (en) * 2010-12-20 2013-11-20 西安力邦医药科技有限责任公司 Lamivudine solid dispersion, and preparation method, pharmaceutical composition and use of the dispersion
WO2013183058A2 (en) 2012-06-07 2013-12-12 Tulip Medical Ltd. Expanded device
EP3091962B1 (en) 2013-12-05 2022-06-08 Epitomee Medical Ltd. Retentive devices and systems for in-situ release of pharmaceutical active agents
BR112016028957B1 (en) 2014-06-11 2021-12-14 The Brigham And Women's Hospital, Inc. GASTRIC RESIDENCE STRUCTURE
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
CA2983272C (en) 2015-05-01 2023-08-29 Massachusetts Institute Of Technology Triggerable shape memory induction devices
WO2017070612A1 (en) 2015-10-23 2017-04-27 Lyndra, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CN108697649A (en) 2015-12-08 2018-10-23 林德拉有限公司 Geometric configuration for stomach resident system
CN110022861A (en) 2016-09-30 2019-07-16 林德拉有限公司 Stomach resident system for Derivatives of Adamantane sustained release
US11337919B2 (en) * 2017-12-18 2022-05-24 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
TR201914116A2 (en) * 2019-09-17 2021-04-21 Univ Yeditepe PRODUCTION METHOD OF NATURAL BIOMATERIALS AND CRYOGELS AND THE USE OF THESE CRYOGELS AS SOFT TISSUE SCACHE OR DRUG CARRIER SYSTEM
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
DE4406424A1 (en) * 1994-02-28 1995-08-31 Bayer Ag Expandable dosage forms
AU8699298A (en) * 1997-08-11 1999-03-01 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
EP1281397A1 (en) * 1998-09-14 2003-02-05 Ranbaxy Laboratories Limited Orally administered controlled drug delivery system providing temporal and spatial control
JP2000256216A (en) * 1999-03-04 2000-09-19 Meiji Milk Prod Co Ltd Gel composition
KR20030013460A (en) * 2000-06-23 2003-02-14 테바 파마슈티컬 인더스트리즈 리미티드 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Also Published As

Publication number Publication date
JP2005501097A (en) 2005-01-13
ZA200402066B (en) 2005-05-09
PL368327A1 (en) 2005-03-21
KR20040032918A (en) 2004-04-17
MXPA04001388A (en) 2004-05-27
BR0117123A (en) 2004-09-28
WO2003015745A1 (en) 2003-02-27
NO20040611L (en) 2004-04-16
CA2456976A1 (en) 2003-02-27
NZ531461A (en) 2008-03-28
CO5670360A2 (en) 2006-08-31
EP1416914A1 (en) 2004-05-12
CN1543337A (en) 2004-11-03

Similar Documents

Publication Publication Date Title
HK1070532A1 (en) Expandable in-ear device
GB0114659D0 (en) Device
GB0107858D0 (en) Device
IL160363A0 (en) Expandable gastric retention device
SG101984A1 (en) Deplexer device
EP1379079A4 (en) Contour-emphasizing device
GB2371229B (en) De-odourising device
GB2376781B (en) Memory device
GB0111329D0 (en) Device
GB0102701D0 (en) Device
GB0111328D0 (en) Device
GB0111336D0 (en) Device
GB2376720B (en) Fluid-propelling device
GB2378421B (en) Multi-embossing device
GB0111330D0 (en) Device
GB0111337D0 (en) Device
GB0110166D0 (en) Shock-shower device
GB0114945D0 (en) Device
GB2383317B (en) Mooring device
GB0104001D0 (en) Gastric drainage device
TW461332U (en) Leg-lifting device
GB0116785D0 (en) Mediical Device
GB0112011D0 (en) Memory Device
GB0117190D0 (en) Memory device
AU146292S (en) Anchoring device